npj Precision Oncol
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival
Digital Display Precision Predictor (DDPP) is potentially a new global biomarker model that can apply to any type of drug alone or in combination, agnostic of tumor type, and can lead, pending further prospective validation, to a new approach to optimal treatment selection for patients with cancer.
Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
Multiplex bioimaging of single-cell profiles in patient biopsies and artificial intelligence analysis of spatially distinct patient cohorts inform personalized cancer treatments.
In our research, PBRM1 mutation was found to be a negative predictive biomarker of immunotherapy efficacy in NSCLC. Patients with PBRM1 mutation got less survival benefit from immunotherapy for NSCLC.